Search Results for "Apokyn"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Apokyn. Results 1 to 9 of 9 total matches.
See also: apomorphine
Apomorphine (Apokyn) for Parkinson's Disease
The Medical Letter on Drugs and Therapeutics • Jan 17, 2005 (Issue 1200)
Apomorphine (Apokyn) for Parkinson's Disease ...
Apomorphine (Apokyn - Mylan/Bertek), an injected non-ergot dopamine agonist, was recently approved by the FDA for intermittent subcutaneous (SC) treatment of hypomobility ("off" episodes) in patients with advanced Parkinson's disease. It has been available in Europe for many years.
Sublingual Apomorphine (Kynmobi) for Parkinson's Disease
The Medical Letter on Drugs and Therapeutics • Oct 19, 2020 (Issue 1609)
of apomorphine
(Apokyn) has been available for years for the same
indication in patients with advanced PD.1 ...
The FDA has approved a sublingual fi lm formulation
of the nonergot dopamine agonist apomorphine
(Kynmobi – Sunovion) for acute, intermittent treatment
of "off" episodes in patients with Parkinson's disease
(PD). A subcutaneous formulation of apomorphine
(Apokyn) has been available for years for the same
indication in patients with advanced PD.
Onapgo — An Apomorphine Subcutaneous Infusion for Parkinson's Disease
The Medical Letter on Drugs and Therapeutics • Jul 21, 2025 (Issue 1733)
). Subcutaneously
injected apomorphine (Apokyn, and generics) has
been available for intermittent use for years.1 ...
Onapgo (Supernus), a solution for continuous
subcutaneous infusion containing the dopamine
agonist apomorphine, has been approved by the FDA
for treatment of motor fluctuations in adults with
advanced Parkinson's disease (PD). Subcutaneously
injected apomorphine (Apokyn, and generics) has
been available for intermittent use for years. Vyalev, a
foscarbidopa/foslevodopa solution for subcutaneous
infusion, was approved in 2024 for the same indication.
Med Lett Drugs Ther. 2025 Jul 21;67(1733):116-8 doi:10.58347/tml.2025.1733d | Show Introduction Hide Introduction
Inhaled Levodopa (Inbrija) for Parkinson's Disease
The Medical Letter on Drugs and Therapeutics • May 20, 2019 (Issue 1572)
dopamine
agonist apomorphine (Apokyn) can be used as rescue
treatment for “off” episodes in patients ...
The FDA has approved Inbrija (Acorda), an orally
inhaled dry-powder formulation of levodopa, for
intermittent treatment of "off" episodes in patients
with Parkinson's disease (PD) being treated with
carbidopa/levodopa (Sinemet, and others).
Istradefylline (Nourianz) for Parkinson's Disease
The Medical Letter on Drugs and Therapeutics • Feb 10, 2020 (Issue 1591)
apomorphine (Apokyn) and an orally inhaled
dry-powder formulation of levodopa (Inbrija) are FDA-approved ...
The FDA has approved istradefylline (Nourianz —
Kyowa Kirin), an oral adenosine A2A receptor antagonist,
for use as an adjunct to carbidopa/levodopa in adults
with Parkinson's disease (PD) who experience "off"
episodes. Istradefylline is the first adenosine A2A
receptor antagonist to be approved in the US; it has
been available in Japan since 2013.
Opicapone (Ongentys) - A COMT Inhibitor for Parkinson's Disease
The Medical Letter on Drugs and Therapeutics • Jan 11, 2021 (Issue 1615)
(Nourianz).1-3
Subcutaneous (Apokyn) or sublingual (Kynmobi)
apomorphine4 or an orally inhaled dry-powder ...
The FDA has approved opicapone (Ongentys –
Neurocrine), a peripherally-acting reversible catechol-O-methyltransferase (COMT) inhibitor, for oral use as an
adjunct to carbidopa/levodopa in adults with Parkinson’s
disease (PD) who experience "off" episodes. It is the
third COMT inhibitor to be approved for this indication;
tolcapone (Tasmar, and generics) and entacapone
(Comtan, and generics) were approved earlier. Opicapone
has been available in Europe since 2016.
Drugs for Female Sexual Dysfunction
The Medical Letter on Drugs and Therapeutics • Dec 13, 2010 (Issue 1353)
irritation and burning have
been reported.
The dopamine agonist apomorphine (Apokyn), which
is injected ...
Sexual complaints related to desire, arousal, orgasm
and painful intercourse are common in women. Since
the last Medical Letter article on this subject, some
new information has become available.
Drugs for Parkinson's Disease
The Medical Letter on Drugs and Therapeutics • Feb 22, 2021 (Issue 1618)
, 8 mg/24 hr patches14 1 patch (4-8 mg) q24 hrs15 712.50
Subcutaneous
Apomorphine – Apokyn (Supernus ...
The motor symptoms of Parkinson's disease (PD) are
caused primarily by degeneration of dopaminergic
neurons in the substantia nigra. The nonmotor symptoms
of the disease are thought to be caused by degeneration of
other neurotransmitter systems. No disease-modifying
drugs are available for treatment of PD.
Comparison Table: Drugs for Parkinson's Disease (online only)
The Medical Letter on Drugs and Therapeutics • Feb 22, 2021 (Issue 1618)
– Apokyn
(Supernus)
30 mg/3 mL cartridges
iSupplied with a reusable pen
injector (Apokyn Pen) and 6 ...
View the Comparison Table: Drugs for Parkinson's Disease